Company news
Jazz Pharmaceuticals plc news in 2022
Jazz Pharmaceuticals plc's news releases, calls and decks from 2022, newest first.
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
December 20, 2022
Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies
December 4, 2022
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting
November 27, 2022
Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)
November 17, 2022
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
November 8, 2022
Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
November 2, 2022
Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022
October 25, 2022
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
October 18, 2022
Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
September 14, 2022
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
August 17, 2022
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
August 2, 2022
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
July 19, 2022
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
June 27, 2022
Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting
June 6, 2022
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine
May 31, 2022
Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference
May 31, 2022
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
May 11, 2022
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
May 8, 2022
Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance
May 3, 2022
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
May 3, 2022
Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference
May 2, 2022
Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
April 19, 2022
Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types
April 7, 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
April 6, 2022
Jazz Pharmaceuticals to Participate in Upcoming April Investor Conferences
March 28, 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics
March 27, 2022
Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing
March 24, 2022
Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors
March 23, 2022
Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting
March 7, 2022
JAZZ Pharmaceuticals announces full year and fourth quarter 2021 financial results
February 28, 2022
Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022
February 14, 2022
Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule
February 1, 2022
Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader
January 9, 2022
Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
January 4, 2022
U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
January 2, 2022
Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022
Calls in 2022
- Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2022 Earnings Call
Nov 9, 2022
Transcript - Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2022 Earnings Call
May 4, 2022
Transcript - Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 2021 Earnings Call
Mar 1, 2022
Transcript
Decks in 2022
- Shareholder Meeting (July 2022)
Shareholder meeting · 11 slides · Jul 7, 2022